These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34659242)

  • 21. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression.
    Wachsmuth LP; Patterson MT; Eckhaus MA; Venzon DJ; Gress RE; Kanakry CG
    J Clin Invest; 2019 Mar; 129(6):2357-2373. PubMed ID: 30913039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneous blockade of costimulatory signals CD28-CD80 and CD40-CD154 combined with monoclonal antibody against CD25 induced a stable chimerism and tolerance without graft-versus-host disease in rat.
    Zhu ZX; Fan LY; Wang Q
    Eur Surg Res; 2011; 46(3):109-17. PubMed ID: 21242693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Donor-specific prolongation of rat skin graft survival induced by rat-donor cells and cyclophosphamide under coadministration of monoclonal antibodies against T cell receptor alpha beta and natural killer cells in mice.
    Umesue M; Mayumi H; Nishimura Y; Kong YY; Omoto K; Murakami Y; Nomoto K
    Transplantation; 1996 Jan; 61(1):116-24. PubMed ID: 8560549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
    Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
    Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia.
    Nagler A; Labopin M; Dholaria B; Angelucci E; Afanasyev B; Cornelissen JJ; Sica S; Meijer E; Ciceri F; Van Gorkom G; Kröger N; Martin H; Pioltelli P; Risitano A; Canaani J; Savani BN; Sanz J; Mohty M
    Clin Cancer Res; 2021 Feb; 27(3):843-851. PubMed ID: 33148668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High-Dose Cyclophosphamide.
    Raiola AM; Risitano A; Sacchi N; Giannoni L; Signori A; Aquino S; Bregante S; Di Grazia C; Dominietto A; Geroldi S; Ghiso A; Gualandi F; Lamparelli T; Tedone E; Van Lint MT; Varaldo R; Ibatici A; Marani C; Marotta S; Guolo F; Avenoso D; Garbarino L; Pane F; Bacigalupo A; Angelucci E
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):119-126. PubMed ID: 29024804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice.
    Eto M; Mayumi H; Tomita Y; Yoshikai Y; Nishimura Y; Maeda T; Ando T; Nomoto K
    J Immunol; 1991 Mar; 146(5):1402-9. PubMed ID: 1671578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen.
    Tomita Y; Khan A; Sykes M
    J Immunol; 1994 Aug; 153(3):1087-98. PubMed ID: 8027542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors.
    Elmariah H; Kasamon YL; Zahurak M; Macfarlane KW; Tucker N; Rosner GL; Bolaños-Meade J; Fuchs EJ; Wagner-Johnston N; Swinnen LJ; Huff CA; Matsui WH; Gladstone DE; McCurdy SR; Borrello I; Gocke CB; Shanbhag S; Cooke KR; Ali SA; Brodsky RA; DeZern AE; Luznik L; Jones RJ; Ambinder RF
    Biol Blood Marrow Transplant; 2018 May; 24(5):1099-1102. PubMed ID: 29452245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence for involvement of clonal anergy in MHC class I and class II disparate skin allograft tolerance after the termination of intrathymic clonal deletion.
    Tomita Y; Nishimura Y; Harada N; Eto M; Ayukawa K; Yoshikai Y; Nomoto K
    J Immunol; 1990 Dec; 145(12):4026-36. PubMed ID: 2147933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistent tolerance induced after portal venous injection of allogeneic cells plus cyclophosphamide treatment.
    Jin T; Sugiura K; Ishikawa J; Lee S; Morita H; Nagahama T; Ikehara S
    Immunobiology; 1999 Jun; 200(2):215-26. PubMed ID: 10416129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism by which additional monoclonal antibody (mAB) injections overcome the requirement for thymic irradiation to achieve mixed chimerism in mice receiving bone marrow transplantation after conditioning with anti-T cell mABs and 3-Gy whole body irradiation.
    Tomita Y; Khan A; Sykes M
    Transplantation; 1996 Feb; 61(3):477-85. PubMed ID: 8610364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of permanent mixed chimerism and skin allograft tolerance across fully MHC-mismatched barriers by the additional myelosuppressive treatments in mice primed with allogeneic spleen cells followed by cyclophosphamide.
    Tomita Y; Yoshikawa M; Zhang QW; Shimizu I; Okano S; Iwai T; Yasui H; Nomoto K
    J Immunol; 2000 Jul; 165(1):34-41. PubMed ID: 10861032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion.
    Eto M; Mayumi H; Tomita Y; Yoshikai Y; Nishimura Y; Nomoto K
    J Immunol; 1990 Sep; 145(5):1303-10. PubMed ID: 2143514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide.
    Mariotti J; Taurino D; Marino F; Bramanti S; Sarina B; Morabito L; De Philippis C; Di Vito C; Mavilio D; Carlo-Stella C; Della Porta M; Santoro A; Castagna L
    Cancer Med; 2020 Jan; 9(1):52-61. PubMed ID: 31702882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The importance of MHC class II in allogeneic bone marrow transplantation and chimerism-based solid organ tolerance in a rat model.
    Timrott K; Beetz O; Oldhafer F; Klempnauer J; Vondran FWR; Jäger MD
    PLoS One; 2020; 15(5):e0233497. PubMed ID: 32442182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolerance induction across Mls and minor histocompatibility complex by inhibiting activation of T helper type 1 in early period.
    Sugiura K; Lee S; Nagahama T; Adachi Y; Ishikawa J; Ikehara S
    Immunol Lett; 2001 May; 77(1):25-30. PubMed ID: 11348666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclophosphamide-induced immunological tolerance: an overview.
    Mayumi H; Umesue M; Nomoto K
    Immunobiology; 1996 Jul; 195(2):129-39. PubMed ID: 8877390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cyclophosphamide-induced immunological tolerance: an overview].
    Mayumi H
    Nihon Geka Gakkai Zasshi; 1996 Dec; 97(12):1097-108. PubMed ID: 9032788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.